Literature DB >> 17021899

Medicolegal aspects of tetrazepam metabolism.

Marion Pavlic1, Kathrin Libiseller, Petra Grubwieser, Heinrich Schubert, Walter Rabl.   

Abstract

The benzodiazepine tetrazepam is primarily muscle relaxant with comparably lower central sedating effects and is therefore commonly prescribed for muscle spasms of different origins. To evaluate tetrazepam metabolism, a study was conducted with ten healthy volunteers. Blood and urine samples were regularly collected after the intake of 50 mg tetrazepam. Toxicological analyses revealed that tetrazepam is also metabolized to diazepam and further to nordazepam, which has not yet been reported. Tetrazepam and diazepam could be detected in urine samples at least 72 h after intake, the diazepam concentration being 33% (+/-14% SD), on average, of the tetrazepam concentration. On the basis of three case histories, the importance of the detection of these newly described metabolites is shown as necessary to prevent false accusations and potential negative legal consequences for examined persons.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17021899     DOI: 10.1007/s00414-006-0118-6

Source DB:  PubMed          Journal:  Int J Legal Med        ISSN: 0937-9827            Impact factor:   2.791


  25 in total

Review 1.  Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics.

Authors:  M Schulz; A Schmoldt
Journal:  Pharmazie       Date:  2003-07       Impact factor: 1.267

2.  Autoxidation of tetrazepam in tablets: prediction of degradation impurities from the oxidative behavior in solution.

Authors:  G Boccardi; C Deleuze; M Gachon; G Palmisano; J P Vergnaud
Journal:  J Pharm Sci       Date:  1992-02       Impact factor: 3.534

Review 3.  Reactions and significance of cytochrome P-450 enzymes.

Authors:  F P Guengerich
Journal:  J Biol Chem       Date:  1991-06-05       Impact factor: 5.157

4.  Quantification of benzodiazepines in whole blood and serum.

Authors:  Franz E Dussy; Cornelia Hamberg; Thomas A Briellmann
Journal:  Int J Legal Med       Date:  2005-10-12       Impact factor: 2.686

5.  [Clinical pilot study of the myogenic effects of flupirtine in comparison to tetrazepam and placebo].

Authors:  M Lobisch; K Schaffler; H Wauschkuhn; B Nickel
Journal:  Arzneimittelforschung       Date:  1996-03

6.  [Death in the bathtub--rectal drug administration].

Authors:  F Musshoff; R Dettmeyer; B Madea
Journal:  Arch Kriminol       Date:  1998 Mar-Apr

7.  [Pharmacokinetic studies following administration of tetrazepam in rhesus monkeys].

Authors:  M Staak; G Sticht; K S Saternus; H Käferstein
Journal:  Beitr Gerichtl Med       Date:  1982

8.  Solubility and stability of tetrazepam in mixed micelles.

Authors:  M A Hammad; B W Müller
Journal:  Eur J Pharm Sci       Date:  1998-12       Impact factor: 4.384

9.  Plasma levels and pharmacokinetics of single and multiple dose of tetrazepam in healthy volunteers.

Authors:  H Bun; F Philip; Y Berger; J Necciari; N R Al-Mallah; A Serradimign; J P Cano
Journal:  Arzneimittelforschung       Date:  1987-02

10.  [Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities].

Authors:  M Pellkofer; M Paulig
Journal:  Med Klin (Munich)       Date:  1989-01-15
View more
  3 in total

1.  Disposition of ketamine and norketamine in hair after a single dose.

Authors:  Ping Xiang; Qiran Sun; Baohua Shen; Min Shen
Journal:  Int J Legal Med       Date:  2010-12-09       Impact factor: 2.686

2.  Chemical submission: results of 4-year French inquiry.

Authors:  S Djezzar; F Questel; E Burin; S Dally
Journal:  Int J Legal Med       Date:  2008-10-17       Impact factor: 2.686

3.  False negative result for amphetamines on the Triage Drug of Abuse panel? The cause of the unusual phenomenon with experimental analyses.

Authors:  Wakako Hikiji; Keiko Kudo; Shinji Sato; Yosuke Usumoto; Akiko Tsuji; Noriaki Ikeda
Journal:  Int J Legal Med       Date:  2008-12-02       Impact factor: 2.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.